CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

83 papers

Active filtersClassification:Supporting

Showing 25-36 of total 83 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype.

Wang Q; Chen Y; Huang D; Wu H; Wu T; Han Y; Cai C; Li J; Shao Y; Ruan J; Jiang H

Jan 1, 2026

2026PubMedSupporting evidence

Next-generation therapeutics for glioblastoma: Challenges and future directions.

Blaquier JB; Lim-Fat MJ; de la Fuente M

Jan 1, 2026Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

2026PubMedSupporting evidence

Heterozygous germline deletion in Hif3a exacerbates esophageal squamous cell carcinoma development.

Qian Y; Lin R; Liu Z; Huang B; Liu X; Su R; Du C; Liu C; Xiao C; Zhang X; Zhang Z; Tian D; Su M

Jan 1, 2026The Journal of pathology

2026PubMedSupporting evidence

The ProTreg21 Protocol: Phase I/IIa Regulatory T cell Therapy Clinical Trial in Deceased-Donor Kidney Transplantation.

Amini L; Kaeda J; Konietschke F; Globke B; Fritsche E; Roemhild A; Kaiser D; Sefrin A; Akyuez L; Haber P; Ritschl P; Choi M; Lichy IM; Goranova I; Volk HD; Öllinger R; Reinke P

Jan 1, 2026Kidney360

2026PubMedSupporting evidence

Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung disease.

Poirier-Blanchette L; Avitzur N; Krustev E

Jan 1, 2026Current opinion in rheumatology

2026PubMedSupporting evidence

Therapeutic ecology of the fiber-microbiota-barrier axis in leukemia: resilience, immune recovery and pharmacomicrobiomics.

Xie R; Jing X

Jan 1, 2026Frontiers in microbiology

2026PubMedSupporting evidence

DMSO and Serum-free cryopreservation of T-cells enabled by glycerol/betaine formulation and controlled-rate freezing with geometry-matched thermal contacts.

Ilie A; Bissoyi A; Tang Q; Oral CB; Grover O; Gibson MI

Jan 1, 2026Cryobiology

2026PubMedSupporting evidence

Impact of IL-21 on CAR T-cell manufacturing: phenotypic, metabolic, and functional outcomes.

Val-Casals M; Altuna A; Pérez-Amill L; Armand-Ugón M; Peña S; López-Pecino A; Colomer D; Esteve J; Juan M; Klein-González N

Jan 1, 2026Frontiers in immunology

2026PubMedSupporting evidence

CRS and ICANS: Early detection and personalized management.

Kim J

Jan 1, 2026Blood research

2026PubMedSupporting evidence

Barriers to Patient Referral and Completion of CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma.

Shadman M; Ahlstrom J; Gutierrez M; Nastoupil L; Porter D; Schmitt A; Zitella L; Graff T

Jan 1, 2026Transplantation and cellular therapy

2026PubMedSupporting evidence

Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.

Asano Y; Veatch JR; Sung CJ; Tang TH; Mazziotta F; Natsuki S; McAfee M; Bakhtiari J; Lee B; Martin L; Rizzi A; Zhang T; Smith CW; Paulson KG; Schmitt TM; Newell EW; Elz AE; Chen DG; Su Y; Gustafson HH; Yeung CCS; Seaton B; Hunter D; Koelle DM; Bhatia S; Hall ET; Voillet V; Cao J; Gooley T; Greenberg PD; Gottardo R; Oda SK; Nghiem P; Chapuis AG

Jan 1, 2026Science translational medicine

2026PubMedSupporting evidence

The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer.

Huang M; Zhang J; Huang H; Liu L; Zou Y

Jan 1, 2026Frontiers in immunology